Ampio Pharmaceuticals (AMPE) 10-Q2018 Q3 Quarterly report

Filed: 14 Nov 18, 6:13am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adequacy, Advisory, analytical, Biosimilar, breached, calendar, canceled, Cetrone, Chairman, Chemistry, clarify, CMC, Colorado, conclusion, confidentially, contingency, CSO, deal, decision, defend, dispute, dollar, efficacy, effort, Fee, fiduciary, footnote, formal, Framework, gather, gathering, individual, insufficiency, juncture, likelihood, LLLP, lobbying, Macaluso, merit, Michael, Moran, motivate, notified, ongoing, persuade, Plante, PLLC, potency, Prescription, quickly, reconsider, rejecting, remote, removed, repriced, repricing, resignation, resigned, retire, review, role, send, serve, Shaffer, Shi, SPA, supposed, testing, Theise, Type, unspecified, unvested, User, vigorously, working, written

Removed: adjust, adjusted, alternative, announced, assessing, automatically, basic, BioScience, calculation, closed, converted, Deferral, discounted, disregard, EPS, fourth, headcount, HSA, Indefinite, indexed, instrument, international, Mandatorily, multiplied, Noncontrolling, Nonpublic, ownership, patient, prepare, Redeemable, rental, Replacement, round, security, significantly, split, successfully, twenty

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AMPE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

AMPIO PHARMACEUTICALS, INC.

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the quarterly report on Form 10-Q for the quarter ended September 30, 2018 (the “Report”) by Ampio Pharmaceuticals, Inc. (the “Company”), each of the undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2018	/s/ Michael Macaluso
	Michael Macaluso
	Chairman and Chief Executive Officer

Dated: November 14, 2018	/s/ Thomas E. Chilcott, III
	Thomas E. Chilcott, III
	Chief Financial Officer, Treasurer and Secretary

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.